Ligand id: 1135

Name: exendin-4

No information available.
Summary of Clinical Use
Approved to treat type 2 diabetes mellitus in patients whose blood sugar is inadequately controlled by other antidiabetes medicines (e.g. metformin, sulphonylureas, thiazolidinediones) or basal insulin. An extended-release formulation for once-weekly administration (called Bydureon® BCiseTM) was FDA approved in October 2017.
Mechanism Of Action and Pharmacodynamic Effects
Acts as a GLP-1 receptor agonist and mimics the action of endogenous GLP-1 peptide in controlling blood sugar levels via improved insulin and glucagon secretion and decreased food intake.
External links